Application of gene EHD2 in preparation of breast cancer immunohistochemical diagnosis reagent

Abstract

The invention relates to an application of a gene EHD2 in preparation of a breast cancer immunohistochemical diagnosis reagent, wherein the general international serial number of the gene EHD2 is NM_014601. The application of the gene EHD2 in preparation of the breast cancer immunohistochemical diagnosis reagent is characterized in that an antibody specific to human EHD2 protein is adopted, the antibody specific to the human EHD2 protein can specifically recognize the human EHD2 protein, and an amino acid sequence of a recognization site is 503-SEQ ID NO:1-543.

Description

Technical field [0001] The present invention relates to the field of biotechnology, in particular, the expression and subcellular localization of EHD2 have a significant correlation with the survival of breast cancer patients, and can be used as a molecular index for breast cancer malignancy diagnosis and prognosis prediction. Background technique [0002] Breast cancer is a common malignant tumor in women. One million women suffer from the disease every year in the world. Since the late 1970s, the incidence of breast cancer in my country has always been the first among female tumors. North America and Northern Europe were originally areas with high incidence of breast cancer. Now the incidence rate in my country has increased from 17 per 100,000 five years ago to 52 per 100,000 last year, showing a rapid upward trend, and the age of onset is also increasing. Younger and younger, the youngest is only fourteen years old. There are many factors that cause breast cancer. In additio...

AI Technical Summary

Problems solved by technology

One is the EHD2 antibody agent of Nanjing Senbega Company, but it is marked that it can only detect membrane localization

The other is the antibody with the product number 11440-1-AP from Proteintech. However, there are problems with the specificity of this antibody: firstly, the main signal position detected by Western blot is obviously less than 60kD, while the signal at the normal position of 70kD is very weak, indicating that although EHD2 can be detected, but other unknown molecules are more detected; secondly, from the immunohistochemical image of the antibody on lung cancer tissue published by the company, it can be seen that the staining signal is obvious non-specific staining of matrix components

[0010] 2. These antibodies are all research reagents, have not been tested or verified in large-scale clinical cases, and have no key ability to detect the nuclear localization of EHD2. Preconditions and foundations for the purpose of predicting the prognosis of malignancy and patient survival

[0011] 3. None of them have undergone strict immunoblotting specificity verification, especially the cross-reaction immunoblotting experiment verification with homologous proteins EHD1, EHD3, and EHD4 of EHD2 protein, and these verifications are especially important for EHD2 immunohistochemical detection methods. Important due to high homology (>70%) between them

[0012] The Chinese literature "Research on EHD2 Downregulation Promotes Mammary Epithelial Cell Transformation" (Tian Gang et al., Journal of Modern Medical Laboratory, 2012, Vol. 27, No. 1, 49-51) discloses a self-made EHD2 antibody, which is It is our antibody that has not been purified by antigen and can be used for western blot detection, but it cannot meet the high specificity requirements of immunohistochemical detection

Images